TSE:4527Personal Products
Will Rohto Pharmaceutical's Upgraded Guidance and Dividend Forecast Alter Its Story (TSE:4527)?
Rohto Pharmaceutical Co., Ltd. recently raised its consolidated earnings guidance for the fiscal year ending March 31, 2026, following stronger-than-expected performance in Japan, Asia, and the Americas, and also announced an increased full-year dividend forecast to JPY 43 per share.
This upward revision reflects confidence in sustained operational growth and an enhanced commitment to returning profits to shareholders as business momentum improves.
We'll explore how Rohto Pharmaceutical's...